A multi-centre collaborative study on the potency estimation of ReFacto

Summary

Seven laboratories estimated factor VIII coagulant activity in recombinant B-domain-deleted (ReFacto) and plasma-derived FVIII concentrates (Octonativ-M) using chromogenic methods relative to the WHO 6th International Standard FVIII Concentrate (WHO 6th IS), European Pharmacopoeia BRP#2 (EP#2) and the ReFacto Laboratory Standard (RLS). Significantly higher estimates were obtained for all batches of product when calculated relative to the RLS in comparison with estimates vs WHO 6th IS and EP#2. Mean estimates for two batches of ReFacto product vs the RLS were within 10% of the labelled potency whereas estimates vs WHO 6th IS and EP#2 ranged from 21 to 31% lower than the label. Conversely, mean estimates for Octonativ-M relative to WHO 6th IS and EP#2 were within 10% of the label whereas the mean estimate vs RLS was 117% of label. Mean estimates for the ReFacto product, vs the WHO 6th IS and EP#2, varied considerably between the different chromogenic kits whereas estimates vs the RLS showed good agreement between kits. Mean estimates for the RLS vs the WHO 6th IS (8.10 IU/vial) and the EP#2 (7.66 IU/vial) were lower than the assigned value of 9.4 IU/vial. The results are consistent with ReFacto and full-length FVIII responding differently to variations in assay methodology and also indicate that the assigned value on the RLS may be too high. Since this study the unitage on the RLS has been adjusted to effectively increase the amount of ReFacto in the product by 20%.

Keywords

Factor VIII - Haemophilia A - chromogenic assays

• References

• 1 Barrowcliffe TW. Recommendations for the assay of high purity Factor VIII concentrates. Thromb Haemost 1993; 70: 876-7.
• 2 Assay of blood coagulation factor VIII. Methods of analysis 2.7.4. European Pharmacopoeia 4th Edition. 2002: 166-8.
• 3 Addiego JE, Gomperts E, Liu S-L. et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
• 4 Sandberg H, Almstedt A, Brandt J. et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
• 5 Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8.
• 6 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
• 7 Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in haemophilia A patients treated with recombinant factor VIII products. Semin Thromb Haemost 2002; 28: 257-64.
• 8 Hubbard AR, Weller LJ, Bevan SA. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957-60.
• 9 Raut S, Heath AB, Barrowcliffe TW. A collaborative study to establish the 6th International Standard for Factor VIII concentrate. Thromb Haemost 2001; 85: 1071-8.
• 10 Finney DJ. Statistical methods in biological assay. 3rd ed. London: Charles Griffin; 1978
• 11 Kirkwood TBL. Geometric means and measures of dispersion. Biometrics 1979; 35: 908-9.
• 12 Duncan DB. T-tests and intervals for comparisons suggested by the data. Biometrics 1975; 31: 339-59.
• 13 Gruppo RA, Brown D, Wilkes MM. et al. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
• 14 EMEA Public Statement on ReFacto (moroctocog alfa) prepared by the Committee for Proprietary Medicinal Products (CPMP) (May 2003). Introduction of a change to ReFacto drug product specific activity specification increase of 20% in the amount of ReFacto protein in each vial. CPMP/2337/03..